Literature DB >> 19455959

[Mucoid impaction of the bronchi caused by Schizophyllum commune which developed after discontinuation of itraconazole administration].

Takashi Ishiguro1, Noboru Takayanagi, Keiji Harasaw, Yutaka Yoshii, Aya Matsushita, Koichiro Yoneda, Yousuke Miyahara, Naho Kagiyama, Daido Tokunaga, Fumiaki Aoki, Hiroo Saito, Mikio Ubukata, Kazuyoshi Kurashima, Tsutomu Yanagisawa, Yutaka Sugita, Yoshinori Kawabata, Katsuhiko Kamei.   

Abstract

We report the case of a 75-year-old woman with mucoid impaction of the bronchi (MIB) due to Schizophyllum commune who improved with itraconazole (ITCZ) administration and relapsed after discontinuation of the drug. She improved again after readministration of ITCZ, and MIB has not recurred. This patient was not suffering from asthma and has been well without steroid administration. Reports of respiratory disorders due to S. commune have been increasing, and cases of allergic bronchopulmonary mycosis (ABPM), fungus ball, lung abscess, and pneumonia have been reported. Including this report, 12 cases of ABPM and MIB due to S. commune have been reported by Japanese authors. Treatment in these 12 cases included anti-fungal agent in 6, single steroid therapy in 3, combination therapy in 2, and bronchial toilet in 1 case. S. commune is not well recognized; however, one should suspect this fungus to be the causative pathogen when Aspergillus species are not detected or anti-Aspergillus antibody is negative.

Entities:  

Mesh:

Substances:

Year:  2009        PMID: 19455959

Source DB:  PubMed          Journal:  Nihon Kokyuki Gakkai Zasshi        ISSN: 1343-3490


  5 in total

1.  Molecular characterization and in vitro antifungal susceptibility profile of Schizophyllum commune, an emerging basidiomycete in bronchopulmonary mycoses.

Authors:  Anuradha Chowdhary; Shallu Kathuria; Pradeep Kumar Singh; Kshitij Agarwal; Shailendra N Gaur; Pradip Roy; Harbans S Randhawa; Jacques F Meis
Journal:  Antimicrob Agents Chemother       Date:  2013-03-18       Impact factor: 5.191

2.  A favorable clinical effect of an expectorant in allergic bronchopulmonary mycosis caused by Schizophyllum commune.

Authors:  Haruki Kobayashi; Tetsuhiko Taira; Kazushige Wakuda; Toshiaki Takahashi; Masahiro Endo
Journal:  Respir Med Case Rep       Date:  2016-07-17

3.  First report on cutaneous infectious granuloma caused by Schizophyllum commune.

Authors:  Lidi Tian; Yunzhu Mu; Hao Zhang; Xiaocui Su; Chuan Yang; Xianzhu Shu; Defu Qing
Journal:  BMC Infect Dis       Date:  2018-06-26       Impact factor: 3.090

4.  Allergic Bronchopulmonary Mycosis Caused by Schizophyllum commune: A Special Interest in Positive Culture of Other Basidiomycetes Fungi.

Authors:  Akihiko Ito; Takashi Ishiguro; Yotaro Takaku; Naho Kagiyama; Katsuhiko Kamei; Noboru Takayanagi
Journal:  Intern Med       Date:  2019-08-21       Impact factor: 1.271

5.  Allergic Bronchopulmonary Mycosis Due to Schizophyllum commune Treated Effectively with Voriconazole.

Authors:  Takashi Ishiguro; Naho Kagiyama; Ayako Kojima; Masami Yamada; Yasuo Nakamoto; Yotaro Takaku; Yoshihiko Shimizu; Kazuyoshi Kurashima; Noboru Takayanagi
Journal:  Intern Med       Date:  2018-03-30       Impact factor: 1.271

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.